ASCO Genitourinary Cancers Symposium
ASCO GU 2022 TROPHY-U-01 Cohort 3: Sacituzumab Govitecan + Pembrolizumab in mUC After Progression With Platinum-Based Regimens
By
ASCO Genitourinary Cancers Symposium
FEATURING
Petros Grivas
By
ASCO Genitourinary Cancers Symposium
FEATURING
Petros Grivas
Login to view comments.
Click here to Login